Influences of Ivabradine treatment on serum levels of cardiac biomarkers sST2, GDF-15, suPAR and H-FABP in patients with chronic heart failure

• 来源期刊: 中国药理学报（英文版）
• 关键词: heart failure cardiomyopathy Ivabradine heart rate biomarker sST2 GDF-15 suPAR H-FABP
• 年，卷（期）: 2018,（7）
• 页码范围: 1189-1196
• 页数: 8页
• 语种: 英文
• DOI: 10.1038/aps.2017.167

摘要

Chronic heart failure (CHF) represents a major cause of hospitalization and death.Recent evidence shows that novel biomarkers such as soluble suppression of tumorigenicity (sST2),growth-differentiation factor-15 (GDF-15),soluble urokinase plasminogen activator receptor (suPAR) and heart-type fatty acid binding protein (H-FABP) are correlated with inflammatory and ischemic responses in CHF patients.In this study we examined the effects of Ivabradine that inhibited the hyperpolarization-activated cyclic nucleotide-gated channel (HCN channel,also called funny current If),thereby leading to selective heart rate reduction and improved myocardial oxygen supply on the cardiac biomarkers sST2,GDF-15,suPAR and H-FABP in 50 CHF patients at the University Hospital of Jena.Patients were divided into three groups based on the etiology of CHF:dilated cardiomyopathy (DCM,n=20),ischemic cardiomyopathy (1CM,n=20) and hypertensive cardiomyopathy (HCM,n=10).The patients were administered Ivabradine (5 mg,bid for 3 months,and 7.5 mg bid for further 3 months).Analyses of cardiovascular biomarkers were performed at baseline as well as at 3-and 6-month follow-ups.At 6-month follow-up,GDF-15 levels were significantly reduced compared to baseline levels (P=0.0215),indicating a reduction in the progress of cardiac remodeling.H-FABP concentration was significantly lower in DCM patients compared to ICM (1.89 vs 3.24 μg/mL) and HCM patients (1.89 vs 3.80 μg/mL),and decreased over the 6-month follow-up (P=0.0151).suPAR median levels remained elevated,implying major ongoing inflammatory processes.As shown by significant decreases in GDF-15 and H-FABP levels,a reduction in ventricular remodeling and sub-clinical ischemia could be assumed.However,markers of hemodynamic stress (sST2) and inflammation (suPAR) showed no change or progression after 6 months of Ivabradine treatment in CHF patients.Further studies are necessary to validate the clinical applicability of these novel cardiovascular biomarkers.